Judge Tosses Vanda's Fight Against FDA's Drug Approval Structure
Key Insights
A federal district court ruled it no longer has jurisdiction over Vanda Pharmaceuticals' challenge to the FDA's drug review process.
Judge Amit Mehta stated that Vanda raised the same Appointments Clause arguments in the D.C. Circuit, which would have precedential effect.
The case centers on Vanda's constitutional challenge to the structure of FDA drug approvals under the Appointments Clause.
A federal district court has dismissed Vanda Pharmaceuticals Inc.'s lawsuit challenging the U.S. Food and Drug Administration's drug review process, ruling that it no longer holds jurisdiction over the matter after the drugmaker petitioned a higher court to review the same constitutional questions.
Judge Amit Mehta of the U.S. District Court for the District of Columbia Circuit issued the order on July 17, explaining that while the district court may have had jurisdiction at the outset, that authority has since been displaced. "Though this court arguably had jurisdiction to resolve the parties' dispute at first, it no longer does," Mehta wrote.
The jurisdictional shift stems from Vanda's decision to raise identical Appointments Clause arguments before the D.C. Circuit Court of Appeals. "Vanda has raised the same Appointments Clause arguments made here in the D.C. Circuit," Mehta noted. "A favorable ruling on that question would have precedential effect, rendering this court's [jurisdiction moot]."
Constitutional Challenge to FDA Review Structure
At the heart of the dispute is Vanda's contention that the FDA's drug approval framework runs afoul of the Appointments Clause of the U.S. Constitution. The pharmaceutical company has argued that certain officials involved in the drug review and approval process hold positions that, under the Constitution, should be filled through a formal appointment process subject to Senate confirmation.
The case represents one of the more notable constitutional challenges to the FDA's regulatory architecture in recent years, with potential implications for how the agency structures its drug review divisions and the legal status of its decision-makers.
Shift to the Appellate Level
With the district court's dismissal, the legal contest now moves squarely to the D.C. Circuit, where Vanda's Appointments Clause arguments will be weighed with potentially binding effect. A ruling from the appellate court would carry precedential weight that a district court decision could not, making the higher court the more consequential venue for resolving the constitutional questions raised.
The outcome of this case could have significant ramifications for the pharmaceutical industry, potentially affecting the validity of past drug approval decisions and shaping how the FDA organizes its review personnel going forward.